Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab Master Protocol Continuation Study
2021-002457-29Phase 4Active
- Sponsor
- Pfizer
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of avelumab in cancer (3 arms), sponsored by Pfizer. Primary endpoint: AEs leading to permanent discontinuation of study intervention. Started Jul 2021; status: active.
02
Drugs
avelumab
03
Conditions
cancer
Beyond the preview
Go deeper on 2021-002457-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002457-29.